---
title: "Haw Par Corporation Limited (H02.SG)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/H02.SG.md"
symbol: "H02.SG"
name: "Haw Par Corporation Limited"
industry: "Pharmaceuticals"
datetime: "2026-05-20T18:36:41.508Z"
locales:
  - [en](https://longbridge.com/en/quote/H02.SG.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/H02.SG.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/H02.SG.md)
---

# Haw Par Corporation Limited (H02.SG)

## Company Overview

Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, The Association of Southeast Asian Nations countries, other Asian countries, and internationally. It manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands; and invests in quoted securities. The company also owns and leases various investment properties. In addition, it provides family and tourist oriented leisure activities primarily in the form of oceanariums.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | SG Market |
| Website | [www.hawpar.com](https://www.hawpar.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.51)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 6 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -6.07% |  |
| Net Profit YoY | 16.29% |  |
| P/B Ratio | 0.85 |  |
| Dividend Ratio | 3.65% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3650537010.21 |  |
| Revenue | 230677524.19 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.29% | C |
| Profit Margin | 115.43% | A |
| Gross Margin | 55.99% | B |
| Revenue YoY | -6.07% | D |
| Net Profit YoY | 16.29% | C |
| Total Assets YoY | 3.29% | C |
| Net Assets YoY | 3.44% | C |
| Cash Flow Margin | 21.52% | D |
| OCF YoY | -6.07% | D |
| Turnover | 0.05 | E |
| Gearing Ratio | 2.87% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Haw Par Corporation Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-6.07%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "16.29%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.85",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.65%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3650537010.21",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "230677524.19",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.29%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "115.43%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "55.99%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-6.07%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "16.29%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.29%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.44%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "21.52%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-6.07%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.05",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "2.87%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 13.70 | 2/6 | 14.35 | 13.41 | 12.38 |
| PB | 0.85 | 1/6 | 0.88 | 0.81 | 0.75 |
| PS (TTM) | 15.82 | 5/6 | 14.91 | 13.31 | 12.20 |
| Dividend Yield | 3.65% | 3/6 | 2.77% | 2.54% | 2.19% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | CMS (8A8.SG) | B | C | C | A | C | B |
| 02 | Haw Par (H02.SG) | B | D | E | A | D | C |
| 03 | TJ DaRenTang USD (T14.SG) | A | D | C | B | D | C |
| 04 | IX Biopharma (42C.SG) | D | C | C | B | C | C |
| 05 | Hyphens Pharma (1J5.SG) | B | D | A | C | C | C |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-10T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.22 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/H02.SG/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/H02.SG/norm.md)
- [Related News](https://longbridge.com/en/quote/H02.SG/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**